# OnCo record nct06003231 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06003231/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06003231", "NCT06003231" ;
  schema:name "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2"@en ;
  schema:description "A phase 2 trial of Disitamab vedotin in non-small-cell lung cancer, ovarian cancer, endometrial cancer and head and neck squamous cell carcinoma, run by Seagen, a wholly owned subsidiary of Pfizer, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06003231/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06003231> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-11-14" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/her2-mutant-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/adc/> ;
  onco:drugs <https://onco.cc/drugs/disitamab-vedotin/> ;
  onco:companies <https://onco.cc/companies/pfizer/> .